<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta name="keywords" content="" />
<meta name="description" content="" />
<meta http-equiv="content-type" content="text/html; charset=utf-8" />
<title>Neural Picks - Free Stock Market Advice Powered By Deep Learning</title>
<link href="//fonts.googleapis.com/css?family=Abel|Arvo" rel="stylesheet" type="text/css" />
<link href="style.css" rel="stylesheet" type="text/css" media="screen" />
</head>
<body>
<div id="wrapper">
<div id="header">
<div id="logo">
<h1><a href="#">neural picks</a></h1>
</div>
</div>
<div id="about">
<h2 class="title">Updated on: 04/18/2021, 16:23:12</h2>
<p><img src="images/pics01.jpg" alt="" width="225" height="225" class="alignleft" /><strong>Disclaimer:</strong> This is a project for fun and none of the stock recommendations here should be executed using real money. I am not a professional stock advisor. All trading decisions and associated risks are your own, and I do not take responsibility for any losses.<br /><br /><strong>About:</strong> Stocks are ranked using Deep Learning according to performance on different quantitative and qualitative metrics. Stocks higher up on the list are predicted to have the highest returns over the next 3 weeks, but daily price swings can vary significantly. Forming a portfolio of multiple stocks can reduce daily risks.<br /><br /><strong>Contribute:</strong> Our mission is to further democratize finance by organizing high-quality publicly available information into actionable rankings. This information is free, however donations are highly appreciated at SegWit Bitcoin Wallet Address: bc1qxv7drjce5hx9l6eyht6ejtx2rex36an78fp82t</p>
<!-- AddToAny BEGIN -->
<div class="a2a_kit a2a_kit_size_32 a2a_default_style">
<a class="a2a_dd" href="https://www.addtoany.com/share"></a>
<a class="a2a_button_facebook"></a>
<a class="a2a_button_twitter"></a>
<a class="a2a_button_email"></a>
<a class="a2a_button_reddit"></a>
</div>
<script async src="https://static.addtoany.com/menu/page.js"></script>
<!-- AddToAny END --></div>
<div id="page">
<div id="content"><div class="post"><h2 class="title"><a href="#">NVCR</a></h2><p class="meta">Rank #1 | $192.5 / share</p><div class="entry">       <p>NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and NovoTTF-100L, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products that are in Phase 2 pilot and Phase 3 pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.</p>       <ul>
       <li>Suggested By Multiple Sources</li>
       <li>Robinhood Adjusted Rating: 37.5%</li>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 64.762%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 79.46%</li>
       <li>Fair Stock Price Estimate: $194.77 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -36.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">VICI</a></h2><p class="meta">Rank #2 | $29.94 / share</p><div class="entry">       <p>VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.</p>       <ul>
       <li>Robinhood Adjusted Rating: 95.775%</li>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 93.827%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 24.48%</li>
       <li>Fair Stock Price Estimate: $17.91 (Stock is Overvalued)</li>
       <li>Insider Trading Transactions Rating: 44.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">KBR</a></h2><p class="meta">Rank #3 | $39.87 / share</p><div class="entry">       <p>KBR, Inc. provides professional services and technologies across the asset and program life-cycle within the government services and hydrocarbons industries worldwide. The company operates through three segments: Government Solutions, Technology Solutions, and Energy Solutions. The Government Solutions segment offers life-cycle support solutions to defense, space, aviation, and other programs and missions for military and other government agencies in the United States, the United Kingdom, and Australia. This segment's services cover from research and development, through systems engineering, test and evaluation, systems integration and program management, to operations support, maintenance, and field logistics. The Technology Solutions segment provides proprietary technologies, equipment and catalyst supply, digital solutions and associated knowledge-based services into a global business for refining, petrochemicals, inorganic, and specialty chemicals, as well as gasification, syngas, ammonia, nitric acid and fertilizers. The Energy Solutions segment offers life-cycle support solutions across the upstream, midstream, and downstream hydrocarbons markets; comprehensive project and program delivery solutions, as well as engineering services, front-end consulting and feasibility studies, sustaining capital construction, turnarounds, maintenance services, and others. This segment provides EPC, and consulting and engineering services for onshore oil and gas; LNG/GTL; oil refining; petrochemicals; chemicals; fertilizers; offshore oil and gas; and floating solutions. KBR, Inc. was founded in 1901 and is headquartered in Houston, Texas.</p>       <ul>
       <li>Robinhood Adjusted Rating: 82.353%</li>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 89.899%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Fair Stock Price Estimate: $42.94 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -12.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">ATH</a></h2><p class="meta">Rank #4 | $55.45 / share</p><div class="entry">       <p>Athene Holding Ltd., a retirement services company, issues, reinsures, and acquires retirement savings products for individuals and institutions in the United States and Bermuda. The company provides annuity retirement solutions to its policyholders; and reinsures multi-year guaranteed annuities, fixed indexed annuities, traditional one-year guarantee fixed deferred annuities, immediate annuities, and institutional products. It also offers funding agreements and group annuities. The company was incorporated in 2008 and is headquartered in Pembroke, Bermuda.</p>       <ul>
       <li>Robinhood Adjusted Rating: 45.455%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 63.303%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Fair Stock Price Estimate: $78.1 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: 24.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">INMD</a></h2><p class="meta">Rank #5 | $87.31 / share</p><div class="entry">       <p>InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. InMode Ltd. offers its products directly in the United States, Canada, the United Kingdom, Spain, Australia, and India, as well as indirectly through distributors in 46 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.</p>       <ul>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">TTD</a></h2><p class="meta">Rank #6 | $718.86 / share</p><div class="entry">       <p>The Trade Desk, Inc. operates as a technology company in the United States and internationally. The company operates a self-service cloud-based platform that allows buyers to create, manage, and optimize data-driven digital advertising campaigns in various advertising formats, including display, video, audio, native and social, and on various devices, such as computers, mobile devices, and connected TV. It also provides data and other value-added services, as well as platform features. The company serves advertising agencies and other service providers for advertisers. The Trade Desk, Inc. was founded in 2009 and is headquartered in Ventura, California.</p>       <ul>
       <li>Robinhood Adjusted Rating: 55.556%</li>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 62.745%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Social Media Sentiment: 66.399%</li>
       <li>Fair Stock Price Estimate: $722.59 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -64.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">SWAV</a></h2><p class="meta">Rank #7 | $138.27 / share</p><div class="entry">       <p>ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company operates in the United States, Germany, rest of Europe, and internationally. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.</p>       <ul>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 72.826%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Fair Stock Price Estimate: $139.82 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -72.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">OKTA</a></h2><p class="meta">Rank #8 | $269.98 / share</p><div class="entry">       <p>Okta, Inc. provides identity management platforms for enterprises, small and medium-sized businesses, universities, non-profits, and government agencies in the United States and internationally. The company offers Okta Identity Cloud, a platform that offers a suite of products to manage and secure identities, such as Universal Directory, a cloud-based system of record to store and secure user, application, and device profiles for an organization; and Single Sign-On that enables users to access their applications in the cloud or on-premise from various devices with a single entry of their user credentials. It also provides Adaptive Multi-Factor Authentication, a product that provides an additional layer of security for cloud, mobile, and Web applications, as well as for data; Lifecycle Management, which enables IT organizations or developers to manage a user's identity throughout its lifecycle; API Access Management that enables organizations to secure APIs; Advanced Server Access to secure cloud infrastructure; and Access Gateway that enables organizations to extend the Okta Identity Cloud from the cloud to their existing on-premise applications. In addition, the company offers customer support and training, and professional services. Okta, Inc. sells its products directly to customers through sales force, as well as through channel partners. The company was formerly known as Saasure, Inc. Okta, Inc. was founded in 2009 and is headquartered in San Francisco, California.</p>       <ul>
       <li>Robinhood Adjusted Rating: 61.538%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 73.81%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 88.46%</li>
       <li>Social Media Sentiment: 71.625%</li>
       <li>Fair Stock Price Estimate: $273.4 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -40.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">RILY</a></h2><p class="meta">Rank #9 | $72.14 / share</p><div class="entry">       <p>B. Riley Financial, Inc., through its subsidiaries, provides collaborative financial services and solutions in North America, Australia, and Europe. The Capital Markets segments offers range of investment banking, corporate finance, consulting, financial advisory, research, securities lending, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. This segment also provides merger and acquisitions, restructuring advisory, initial and secondary public offerings, and institutional private placements services; asset management services; manages various private and public funds for institutional and individual investors; and trades in equity securities. The Auction and Liquidation Segment offers retail store liquidation, and wholesale and industrial assets disposition services. The Valuation and Appraisal segment provides valuation and appraisal services, which include valuation of assets to financial institutions, lenders, private equity firms, and other capital provider. The Principal Investments - United Online and magicJack segment provides consumer subscription services consisting of Internet access services and devices under the NetZero and Juno brands, as well as voice over IP cloud-based technology and communication services. The Brands segments provides licensing of a brand investment portfolio, including Catherine Malandrino, English Laundry, Joan Vass, Kensie Girl, Limited Too, and Nanette Lepore. In addition, it offers advisory services to private funds, and institutional and high net worth investors; brokerage services; senior secured and second lien secured loans to middle market public and the private U.S. companies; and consulting services to shareholders, creditors, and companies. The company was formerly known as Great American Group, Inc. and changed its name to B. Riley Financial, Inc. in November 2014. B. Riley Financial, Inc. was founded in 1973 and is headquartered in Los Angeles, California.</p>       <ul>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Fair Stock Price Estimate: $73.7 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: 48.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">GMAB</a></h2><p class="meta">Rank #10 | $35.23 / share</p><div class="entry">       <p>Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.</p>       <ul>
       <li>Robinhood Adjusted Rating: 65.979%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 80.755%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Recent Death Cross</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">MBIN</a></h2><p class="meta">Rank #11 | $40.49 / share</p><div class="entry">       <p>Merchants Bancorp (Indiana) is a bank holding company, which specializes in a multiple lines of business in banking and finance. The company is headquartered in Carmel, Indiana and currently employs 259 full-time employees. The Bank operate multiple lines of business with a focus on FHA multi-family housing and healthcare facility financing and servicing, mortgage warehouse financing, retail and correspondent residential mortgage banking, agricultural lending and traditional community banking. The Bank operates in three primary segments: Multi-family Mortgage Banking, Mortgage Warehousing, and Banking. The Multi-family Mortgage Banking segment originates and services government sponsored mortgages for multi-family and healthcare facilities. The Mortgage Warehousing segment funds agency eligible residential loans from origination or purchase to sale in the secondary market, as well as commercial loans to non-depository financial institutions. The Banking segment provides a wide range of financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage and other consumer loan products.</p>       <ul>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 79.46%</li>
       <li>Fair Stock Price Estimate: $46.75 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: 8.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">WB</a></h2><p class="meta">Rank #12 | $49.48 / share</p><div class="entry">       <p>Weibo Corporation, through its subsidiaries, operates as a social media platform for people to create, distribute, and discover content in the People's Republic of China. It operates in two segments, Advertising and Marketing Services; and Value-Added Services. The company offers discovery products to help users discover content on its platform; self-expression products that enable its users to express themselves on its platform; and social products to promote social interaction between users on its platform. It also provides advertising and marketing solutions, such as social display advertisements; and promoted feeds, such as Super FST, Fans Headline, and Weibo Express, promoted accounts, and promoted trends and search products that enable its customers to promote their brands and conduct marketing activities. In addition, the company offers copyright content, such as TV channels, online video websites, and operators with copyright content through traffic resource exchange and content traffic sharing; MCNs and other self-media to manage and provide services to content creators on Weibo, such as MCNs, unions, and e-commerce partners; other app developers an application platform, which allows users to log into third-party applications; and Weibo Wallet product consists of red envelops and coupons that enables platform partners to conduct interest generation activities on Weibo. The company was formerly known as T.CN Corporation and changed its name to Weibo Corporation in 2012. The company was founded in 2009 and is headquartered in Beijing, China. Weibo Corporation is a subsidiary of Sina Corporation.</p>       <ul>
       <li>Robinhood Adjusted Rating: 62.222%</li>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 79.365%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Fair Stock Price Estimate: $68.22 (Stock is Undervalued)</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">MED</a></h2><p class="meta">Rank #13 | $237.09 / share</p><div class="entry">       <p>Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by Take Shape for Life, and Flavors of Home brands. The company markets its products through direct ecommerce platform and franchise weight control center channels. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.</p>       <ul>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 79.46%</li>
       <li>Social Media Sentiment: 50.048%</li>
       <li>Fair Stock Price Estimate: $250.13 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -20.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">MRNA</a></h2><p class="meta">Rank #14 | $170.81 / share</p><div class="entry">       <p>Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.</p>       <ul>
       <li>Robinhood Adjusted Rating: 51.613%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 69.277%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 82.35%</li>
       <li>Social Media Sentiment: 86.169%</li>
       <li>Fair Stock Price Estimate: $178.12 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -56.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">VRTX</a></h2><p class="meta">Rank #15 | $219.39 / share</p><div class="entry">       <p>Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.</p>       <ul>
       <li>Robinhood Adjusted Rating: 88.889%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 91.289%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Social Media Sentiment: 19.736%</li>
       <li>Fair Stock Price Estimate: $242.12 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -92.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">FLGT</a></h2><p class="meta">Rank #16 | $90.5 / share</p><div class="entry">       <p>Fulgent Genetics, Inc. operates as a technology company, which provides genetic testing and next generation sequencing solutions. The company is headquartered in Temple City, California and currently employs 123 full-time employees. The firm offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The firm has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company's test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The firm's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.</p>       <ul>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Social Media Sentiment: 57.162%</li>
       <li>Fair Stock Price Estimate: $94.1 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -84.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">NVAX</a></h2><p class="meta">Rank #17 | $227.35 / share</p><div class="entry">       <p>Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. It has a partnership agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.</p>       <ul>
       <li>Financial Modeling Prep Rating: 0.0%</li>
       <li>Finnhub Adjusted Rating: 89.796%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 58.41%</li>
       <li>Social Media Sentiment: 24.489%</li>
       <li>Fair Stock Price Estimate: $236.97 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -60.0%</li>
       </ul>
</div></div></div>
</div>
</div>
<div id="footer">
<p>&copy; Jonathan Davies. All rights reserved. Design by <a href="http://templated.co" rel="nofollow">TEMPLATED</a>.</p>
</div>
</body>
</html>